Maj Invest Holding A S Sells 105,594 Shares of Johnson & Johnson (NYSE:JNJ)

Maj Invest Holding A S lowered its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 678,082 shares of the company's stock after selling 105,594 shares during the quarter. Johnson & Johnson accounts for 3.2% of Maj Invest Holding A S's investment portfolio, making the stock its 17th largest holding. Maj Invest Holding A S's holdings in Johnson & Johnson were worth $98,066,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Summit Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock valued at $1,463,000 after purchasing an additional 61 shares in the last quarter. Powers Advisory Group LLC lifted its holdings in shares of Johnson & Johnson by 0.6% in the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after acquiring an additional 61 shares during the last quarter. Eagle Wealth Strategies LLC boosted its stake in shares of Johnson & Johnson by 2.8% in the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock valued at $372,000 after purchasing an additional 63 shares in the last quarter. Knuff & Co LLC grew its holdings in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock valued at $1,534,000 after purchasing an additional 64 shares during the last quarter. Finally, Perkins Coie Trust Co increased its position in Johnson & Johnson by 1.8% during the 3rd quarter. Perkins Coie Trust Co now owns 3,705 shares of the company's stock worth $600,000 after purchasing an additional 65 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 1.1 %

JNJ traded up $1.72 during midday trading on Thursday, reaching $152.87. 2,045,698 shares of the company were exchanged, compared to its average volume of 9,333,421. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company's fifty day moving average price is $147.73 and its 200 day moving average price is $156.10. The company has a market cap of $368.05 billion, a price-to-earnings ratio of 22.98, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period last year, the business earned $2.29 EPS. The business's revenue was up 5.3% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.24%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm's stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research analyst reports. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, January 23rd. Guggenheim increased their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Wells Fargo & Company lowered their price objective on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Finally, Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $170.44.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.